211108-48-4

Basic information

• Product Name: tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate
• Synonyms: tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate;tert-butyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate;tert-Butyl 4-((triMethylsilyl)oxy)-5,6-dihydropyridine-1(2H)-carboxylate;tert-Butyl 4-((trimethylsilyl)
• CAS NO: 211108-48-4
• Molecular Formula: C₁₃H₂₅NO₃Si
• Molecular Weight: 271.44
• Mol File: 211108-48-4.mol
• Article Data: 45

Chemical Properties

• Boiling Point: 300.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.00±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.59±0.40(Predicted)
• CAS DataBase Reference: tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate(211108-48-4)
• EPA Substance Registry System: tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate(211108-48-4)

Safety Data

• Hazardous Substances Data: 211108-48-4(Hazardous Substances Data)

Usage

General Description

"Tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate" is a chemical compound that is commonly used in the pharmaceutical industry. It is a crystalline solid with a molecular formula of C14H25NO3Si and a molecular weight of 287.44 g/mol. tert-Butyl 4-[(Trimethylsilanyl)oxy]-3,6-dihydro-2H-pyridine-1-carboxylate is often used as a precursor in the synthesis of various pharmaceutical drugs and agrochemicals. It has a wide range of applications in the production of medicines, herbicides, and pesticides. Additionally, it is also used as a building block in the synthesis of complex organic molecules in research and industrial settings.

Upstream product

• 27607-77-8 trimethylsilyl trifluoromethanesulfonate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 188869-05-8 tert-butyl 3-bromo-4-oxo-piperidine-1-carboxylate 
• 1174020-44-0 tert-butyl (3S,4S)-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 1174020-43-9 tert-butyl (3R,4R)-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 907572-24-1 tert-butyl (3S,4R)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 
• 907572-28-5 tert-butyl-(3R,4S)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 
• 211108-52-0 (±)-cis-4-benzylamino-3-fluoropiperidine-1-carboxylic acid tert-butyl ester 
• 211108-52-0 trans-4-benzylamino-1-tert-butoxycarbonyl-3-fluoropiperidine 
• 1070896-84-2 (anti)-3-fluoro-4-methanesulfonyloxypiperidine-1-carboxylic acid tert-butyl ester 
• 577691-56-6 cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 cis-4-benzylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 
• 211108-52-0 trans-4-benzylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 
• 907544-17-6 tert-butyl (3R,4S)-4-amino-3-fluoropiperidine-1-carboxylate 
• 907544-20-1 (3S,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 577691-56-6 (3S,4S)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 

Relevant articles and documents

Development of the Convergent, Kilogram-Scale Synthesis of an Antibacterial Clinical Candidate Using Enantioselective Hydrogenation

Early chemical development studies into the best way of assembling AZD9742, an antibacterial drug candidate, have involved swapping the order of two reductive aminations. The orthogonally functionalized aminopiperidine partner for these couplings is now enantioselectively synthesized using ruthenium-catalyzed asymmetric hydrogenation. The challenge of controlling defluorination through an appropriate catalyst choice has hitherto prevented this revised sequence from reaching its full potential. However, it is still shown to allow access to the active pharmaceutical ingredient in a stereochemically pure form and has been demonstrated on a multikilogram scale. The reductive aminations in both the original and revised sequences provided different scale-up challenges, and the solutions implemented are described.

FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.(Formula I) (I)

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.